Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

BACKGROUND: The randomised phase III TURANDOT trial compared first-line bevacizumab–paclitaxel (BEV–PAC) vs bevacizumab–capecitabine (BEV–CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point)...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260030/
https://www.ncbi.nlm.nih.gov/pubmed/25268370
http://dx.doi.org/10.1038/bjc.2014.504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260030/
https://www.ncbi.nlm.nih.gov/pubmed/25268370
http://dx.doi.org/10.1038/bjc.2014.504

Ejemplares similares